Practice parameter: Initiation of treatment for Parkinson's disease: An evidence-based review: Report of the quality standards subcommittee of the American Academy of Neurology

Neurology

Volumn 58, Issue 1, 2002, Pages 11-17

  Miyasaki, J M ^a   Martin, W ^a   Suchowersky, O ^a   Weiner, W J ^a   Lang, A E ^a  

^a AMERICAN ACADEMY OF NEUROLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; CABERGOLINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PRAMIPEXOLE; ROPINIROLE; SELEGILINE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DYSKINESIA; EVIDENCE BASED MEDICINE; HUMAN; META ANALYSIS; MOTOR ACTIVITY; NEUROPROTECTION; PARKINSON DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 0037039267     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.58.1.11     Document Type: Review

References (31)

1. Prevalence of parkinsonian signs and associated mortality in a community population of older people
2. Cost-effectiveness analysis in Parkinson's disease: Determining the value of interventions
3. Costs of drug treatment in Parkinson's disease
4. Practice parameters: Initial therapy of Parkinson's disease
5. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications
6. A five-year study of dyskinesias in patients with early Parkinson's disease who were treated with ropinirole or levodopa
7. Pramipexole versus levodopa as initial treatment for Parkinson's disease
8. Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients
9. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease
10. An analysis of treatment options and outcome in patients with Parkinson's disease and severe dyskinesias
11. Impact of Parkinson's disease and its pharmacologic treatment on quality of life and economic outcomes
12. Lisuride, a dopamine agonist in the treatment of early Parkinson's disease
13. Long-term treatment of Parkinson's disease with bromocriptine
14. A six-month study of pergolide and levodopa in de novo Parkinson's disease patients
15. Bromocriptine in Parkinson's disease: A double blind study comparing 'low-slow' and 'high-fast' introductory dosage regimens in de novo patients
16. On-off phenomenon: Relation to levodopa pharmacokinetics and pharmacodynamics
17. Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease
18. Comparison of the therapeutics effects and mortality data of levodopa and levodopa combined combined with selegiline in patients with early, mild Parkinson's disease
19. Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenyl-pyridinium ion
20. Effect of deprenyl on the progression of disability in early Parkinson's disease
21. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease
22. Selegiline delays the onset of disability in de novo parkinsonian patients
23. Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease
24. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa
25. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa
26. Effect of selegiline on mortality in patients with Parkinson's disease. A meta-analysis
27. Mortality in DATATOP: A multicenter trial in early Parkinson's disease
28. The initial treatment of Parkinson disease should begin with levodopa
29. Treatment of Parkinson's disease should begin with a dopamine agonist
30. Cabergoline in the treatment of early Parkinson's disease: Results of the first year of treatment in a double-blind comparison of cabergoline and levodopa
31. Immediate-release and controlled-release carbidopa/levodopa in PD: A 5 year randomized multicenter study